One linked filing — more sources may join as they report · filed Feb 1, 2024. View entity profile → Other incidents for this victim →
incident inc_032f115028b545f0 · merge_method deterministic
Not recorded for this incident
Discovery variance · Leak precedence · Materiality delta · SEC filing delay · Filing span — no leak-site claim in this cluster; needs two dated filings.
FEDERAL
all SEC 10-K Item 1C
Earliest sighting first · deep chronology in Litigation Timeline
ARCA biopharma's FY2023 Form 10-K Item 1C cybersecurity disclosure describes risk management processes, governance (CFO/COO oversight with IT consultant and audit committee), and third-party assessments. The Company explicitly states it has not encountered cybersecurity challenges that have materially impaired its operations or financial standing. No specific cybersecurity incident is disclosed.
About this clustering
DisclosureLens links filings into incidents through layered matchers: deterministic rules (same source document, multistate filings of one breach, tight-window same-victim pairs), a weighted-similarity scorer for cross-source candidates, and an operator review queue for everything uncertain. Each link records its own method and confidence — shown per filing in the timeline below. The system defaults to NOT merging when uncertain, because a false merge (collapsing two unrelated breaches) is more harmful than a false split (showing related filings separately); uncertain pairs route to human review instead of auto-merging. Filing summaries shown in the timeline are AI-generated extracts — verify each against its linked source.